Chronic Lymphocytic Leukemia Coverage from Every Angle
Advertisement
Advertisement

Recent News

Rare Case of Acute Macular Neuroretinopathy in a Woman With CLL
AACR 2021: T-Cell Infusion Product Under Investigation in Resistant CLL
Concurrent Adenoid Cystic Carcinoma and CLL: Case Report
Response to Induction Therapy and Ofatumumab Consolidation in Patients With CLL
Identifying Prognostic Markers for Early-Stage CLL
Novel Agent Under Study in CLL: Dual Inhibitory Activity Reported
High-Risk CLL: GENUINE Trial of Ublituximab Plus Ibrutinib Versus Ibrutinib Alone
BTK Inhibitor and Cerebral Invasive Aspergillosis: Case Report in CLL
Toxicity and Treatment Discontinuation in CLL: U.S. Veterans Health Administration Study
Successful Addition of a New Treatment Arm to the Phase III FLAIR Trial in CLL
Subclinical Coagulopathy Associated With Obinutuzumab Infusion for CLL?
Preclinical Study of Combination Therapy for CLL: Avadomide Plus Checkpoint Inhibition
Case Report in CLL: Is Sclerouveitis an Off-Target Effect of Ibrutinib Treatment?
Blood Clots: New Adverse Event With First Infusion of Obinutuzumab for CLL?
Case Study: Personalized Low-Dose Immunotherapy for Poor-Prognosis CLL
Ibrutinib Versus Idelalisib Plus Rituximab in Resistant CLL
Blood Eosinophil Count and Prognosis in CLL
TCT 2021: Case of Accelerated-Phase CLL/SLL Relapsing as PTCL After Transplantation
TCT 2021: Update on Transplant Outcomes for CLL in Australasia
Case Report: CLL With Right Temporal Lobe Tumor
Reports of Rare Translocation in Chinese Patients With CLL
Using a Whole-Blood Loop Assay to Characterize Immune Response to Rituximab
COVID-19 and CLL: A Spanish Perspective
Pilot Study of Rituximab Biosimilar in Newly Diagnosed CLL
Novel STAT3 Inhibitor Under Study in CLL
Does Idelalisib Increase the Risk of Bleeding Events in Patients With CLL?
Lisocabtagene Maraleucel for Resistant CLL: Phase I Trial Update
Early Study of Lisocabtagene Maraleucel Plus Ibrutinib in Resistant CLL
FDA Brief: Rituximab Biosimilar Approved for Treatment of CLL
ASH 2020: 5-Year Update From MURANO on Venetoclax Versus Bendamustine in Resistant CLL
ASH 2020: Long-Term Update on Ibrutinib Plus Venetoclax in CLL
ASH 2020: PI3K Inhibitor Plus Monoclonal Antibody Versus Chemoimmunotherapy for CLL
ASH 2020: Early-Phase Study of Noncovalent BTK Inhibitor in CLL
ASH 2020: Phase II CAPTIVATE Study Update on Ibrutinib Plus Venetoclax in CLL
Case Report of COVID-19 Infection Unmasking CLL
Use of Ibrutinib During COVID-19–Induced Respiratory Failure in CLL: Case Study
Novel Mutation and CLL Resistance to BTK and SYK Inhibition: Case Study
Exploring Rapid Dose Escalation of Venetoclax in Patients With CLL
Personalizing Management of CLL: From the Advanced Practitioner Perspective
Can LCK Deletion Result in Acceleration of CLL?
Comparing Front-Line Treatments in CLL: Focus on Acalabrutinib


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.